Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Immutep Limited IMMP
$1.58
-$0.03 (-2.17%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
145837013.00000000
-
week52high
3.39
-
week52low
1.47
-
Revenue
-77293
-
P/E TTM
0
-
Beta
2.00419800
-
EPS
-0.28000000
-
Last Dividend
0.00000000
-
Next Earnings Date
23 февр 2023 г. в 05:00
Описание компании
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Ladenburg Thalmann | Buy | 03 авг 2021 г. | |
| Maxim Group | Buy | Buy | 29 мая 2018 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
7 Best Penny Stocks Under $3 to Buy in April
InvestorPlace
12 апр 2023 г. в 19:55
There are speculative ideas and then there are the best penny stocks under $3. And don't be fooled by the word “best.
Why Did Immutep Ltd Stock Soar Recently?
MarketBeat
28 дек 2022 г. в 02:01
Analysts and investors alike appear enamored with Immutep Ltd, whose earnings are growing; more of which could come from their latest product candidate.
Immutep to Participate in Two Upcoming Investor Conferences
GlobeNewsWire
01 ноя 2022 г. в 19:59
Media Release
Immutep to Participate in Two Upcoming Investor Conferences
GlobeNewsWire
26 сент 2022 г. в 08:00
SYDNEY, AUSTRALIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today announced that Marc Voigt, CEO, and Deanne Miller, COO, will participate in two upcoming investor conferences.
Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player
Seeking Alpha
12 июн 2022 г. в 08:51
Immutep has been developing anti-LAG3 compounds for over a decade. Recent approval of the first such compound from BMY was a watershed event.